[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peritoneal-metastasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peritoneal-metastasis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,79,101,126,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100624138","phase-2-lubiprostone-combined-with-maintenance-therapy-for-prevention-of-postoperative-recurrence-in-peritoneal-metastatic-colorectal-cancer-100624138",false,"NCT07405736","Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer","Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer, A Randomized Controlled Phase II Study","Inclusion Criteria:\n\n* Voluntarily participates and provides written informed consent.\n* Histologically confirmed colon\u002Frectal adenocarcinoma with molecular status confirmed as pMMR or MSS.\n* Cytoreductive surgery (CRS) achieves CC0\u002FCC1 cytoreduction.\n* No extraperitoneal metastasis prior to treatment.\n* ECOG performance status 0-1 with adequate organ function per protocol requirements.\n\nExclusion Criteria:\n\n* Extensive multisystem metastases on baseline imaging assessment.\n* Tumor carrying BRAF V600E mutation.\n* dMMR\u002FMSI-H, or confirmed pathogenic POLE\u002FPOLD1 mutation(s).\n* Cachexia or decompensated organ dysfunction.\n* History of another malignancy within the past 5 years.\n* Known or suspected hypersensitivity\u002Fallergy to the study drug or related formulations.\n* Multiple primary cancers.\n* Any serious disease or other medical, psychological, or social condition that, in the investigator's judgment, may compromise participant safety or affect study results.","ALL","18 Years","75 Years",{"count":20,"type":21},124,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this phase II randomized controlled clinical trial is to evaluate whether adding lubiprostone to standard postoperative maintenance therapy can delay disease progression and recurrence in adult patients with colorectal cancer and peritoneal metastases (PM-CRC) who have undergone cytoreductive surgery with or without HIPEC after systemic treatment. The main questions it aims to answer are:\n\nDoes lubiprostone plus maintenance therapy improve the 1-year progression-free survival (PFS) rate compared with maintenance therapy alone?\n\nIs lubiprostone safe and feasible for long-term use during the maintenance period in this PM-CRC population?\n\nResearchers will compare lubiprostone + maintenance therapy versus maintenance therapy alone to see if the addition of lubiprostone prolongs PFS, reduces the risk of distant metastasis, improves overall survival, and maintains or improves quality of life.\n\nParticipants will:\n\nBe randomly assigned to receive maintenance therapy with lubiprostone or maintenance therapy alone after surgery (CRS ± HIPEC) and prior systemic therapy, according to the study protocol.\n\nUndergo scheduled follow-up assessments for disease status (progression\u002Frecurrence), survival outcomes, treatment-related toxicity, and quality of life using the EORTC QLQ-C30 (v3.0) questionnaire.",[27,28,29,30,31],"Colorectal Cancer Metastatic","Peritoneal (Metastatic) Cancer","Peritoneal Metastasis","Colorectal Cancer (CRC)","MSS Metastatic Colorectal Cancer",[33,34,35,36,37,38],"Peritoneal metastasis","Colorectal cancer","Maintenance therapy","Lubiprostone","Cytoreductive Surgery","Progression-free survival","NOT_YET_RECRUITING","2026-02-10",{"date":42,"type":43},"2026-02-12","ACTUAL",{"date":45,"type":21},"2026-02-24",{"date":47,"type":21},"2028-06-01",{"name":49,"class":50},"Sun Yat-sen University","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100619778","phase-1-a-prospective-safety-and-efficacy-clinical-trial-of-pressurized-intraperitoneal-aerosol-therapy-for-peritoneal-metastasis-of-colorectal-cancer-100619778","NCT07349043","A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer","Inclusion Criteria:\n\n1. Patients with peritoneal metastatic adenocarcinoma of colorectal origin, confirmed by histopathology, and without metastasis to other sites.\n2. No gender limitation, aged 18 to 75 years old;\n3. ECOG score ≤2;\n4. Subjects without other malignant diseases;\n5. Subjects without laparoscopic surgery contraindications;\n6. Expected survival period \\> 6 months;\n7. Able to comprehend and sign the informed consent form;\n8. The function of important organs should meet the following requirements; The absolute neutrophil count (ANC) is ≥1.5×10\\^9\u002FL; Platelets ≥ 100×10\\^9\u002FL; Hemoglobin ≥8.0g\u002Fdl (Note: It is acceptable to achieve hemoglobin ≥8.0g\u002Fdl through blood transfusion or other interventions); serum albumin ≥2.8g\u002FdL; Bilirubin ≤1.5 times ULN, ALT and AST ≤1.5 times ULN; if there is liver metastasis, ALT and AST ≤5 times ULN; Creatinine clearance rate ≥50mL\u002Fmin\n\nExclusion Criteria:\n\n1. Subjects with gastrointestinal obstruction;\n2. Subjects who rely entirely on parenteral nutrition;\n3. Subjects with decompensated ascites;\n4. Subjects with severe abdominal infection (peritonitis);\n5. Subjects with extensive abdominal adhesion;\n6. Subjects who underwent both tumor reduction surgery and gastrointestinal resection and reconstruction simultaneously;\n7. Subjects with portal vein thrombosis;\n8. Patients with severe or uncontrolled medical conditions and infections (including atrial fibrillation, angina pectoris, heart failure, ejection fraction less than 50%, refractory hypertension, etc.);\n9. Previously allergic to chemotherapy drugs;\n10. Individuals with severe heart and lung, liver and kidney, blood system, or mental illnesses, as well as those who abuse drugs;\n11. Pregnant or lactating women;\n12. Patients who have participated in or are currently participating in other clinical trials within 3 months;\n13. Other situations where the researchers believe that the patient is not suitable to participate in this trial;\n14. Previously had a history of neurological or psychiatric disorders that would affect study informed consent or follow-up evaluation, such as severe depression or dementia;",{"count":58,"type":21},42,[60],"PHASE1","For colorectal cancer with peritoneal metastasis, the current first-line standard treatment offers very limited benefits and short survival. Therefore, it is necessary to seek new treatment strategies to improve the prognosis and survival of such patients. Based on previous basic research and early clinical research results, the strategy of PIPAC combined with MMC or RTX provides a feasible solution that can benefit patients with advanced colorectal cancer and peritoneal metastasis undergoing first-line treatment. This study aims to evaluate the effectiveness of PIPAC combined with MMC or RTX as first-line treatment for patients with colorectal cancer and peritoneal metastasis, while ensuring that patients receive standard first-line treatment. (The main purpose of the proposed Phase I trial is to determine the MTD of PIPAC combined with MMC or RTX and evaluate the safety of combining it with systemic chemotherapy for patients with colorectal cancer and peritoneal metastasis.)",[29,63],"CRC (Colorectal Cancer)",[65,66,67],"peritoneal metastasis","CRC","PIPAC","RECRUITING","2026-01-08",{"date":71,"type":43},"2026-01-16",{"date":73,"type":21},"2026-01",{"date":75,"type":21},"2028-10",{"name":77,"class":50},"Second Affiliated Hospital, School of Medicine, Zhejiang University",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":78},"100601218","phase-2-a-phase-ii-clinical-study-to-evaluate-the-efficacy-and-safety-of-technetium-99mtc-h7nd-injection-in-the-diagnosis-of-peritoneal-metastasis-of-gastrointestinal-malignant-tumor-100601218","NCT07107633","A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.","A Multicenter, Open-access, Self-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mTc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignancies.","Inclusion Criteria:\n\nOnly those who meet all the following requirements are eligible to join the group:\n\n1. Adults over 18 years of age (based on the time when the informed consent form was signed) can be male or female;\n2. Subjects with gastrointestinal malignant tumor confirmed by histology\u002Fcytology;\n3. Subjects to be surgically removed or explored;\n4. The estimated survival time is ≥12 weeks;\n5. Subjects of childbearing age agreed to adopt effective contraceptive measures during the study period;\n6. Subjects fully understand the purpose, nature, methods and possible adverse reactions of the experiment, voluntarily participate in and sign a written informed consent, and are willing to follow the requirements of the protocol to complete the study.riteria:\n\nThose who meet one of the following items are not allowed to join the group:\n\n1. According to the researcher's judgment, during the screening period, from the imaging examination to the comprehensive real diagnosis information result, the patients were treated with anti-digestive tract tumor;\n2. symptomatic brain metastases who need treatment;\n3. Have serious cardiovascular and cerebrovascular diseases;\n4. There are other contraindications for imaging examination of the research plan, such as claustrophobia;\n5. Have a history of other malignant tumors;\n6. Pregnant (pregnancy test positive in screening period) or lactating women;\n7. Other circumstances that the researcher considers inappropriate to participate in this clinical trial.",{"count":87,"type":21},90,[24],"The main purpose of this study is to evaluate the effectiveness of technetium \\[99mTc\\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To evaluate the safety of technetium \\[99mTc\\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To explore the diagnostic threshold of technetium \\[99mTc\\]-H7ND injection for peritoneal metastasis of gastrointestinal malignant tumor.",[91,29],"Solid Tumor","2025-08-04",{"date":94,"type":43},"2025-08-06",{"date":96,"type":43},"2025-03-12",{"date":98,"type":21},"2025-09",{"name":100,"class":50},"Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100589697","the-value-of-68ga-fapi-petct-for-evaluating-peritoneal-treatment-response-100589697","NCT06957782","The Value of 68Ga-FAPI PET\u002FCT for Evaluating Peritoneal Treatment Response","INTERACT-FAPI","Inclusion Criteria:\n\n* A planned start of repeated IP chemotherapy (with or without the combination of systemic chemotherapy) for macroscopic peritoneal metastases;\n* WHO-performance score of 0 to 1;\n* Aged 18 years or older;\n* Written informed consent according to the ICH-GCP and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Impaired renal function, defined as eGFR \\\u003C25 ml\u002Fmin\u002F1,73 m2. An exception can be made in consultation with the treating physician;\n* Pregnancy\u002Fbreastfeeding. For the latter, temporary discontinuation may be considered;\n* Known allergic reaction to therapeutic radiopharmaceuticals;\n* Inability to lie still on the back for the duration of PET-CT;\n* Any (other) condition, disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that may affect the interpretation of the results, or which might contribute substantially to the patient's experience of study burden (such as non-suppressible claustrophobia).",{"count":109,"type":21},16,[111],"NA","Peritoneal metastases (PM), commonly originating from gastrointestinal and ovarian cancers, are associated with a poor prognosis and limited treatment options due to the diffuse nature of the disease and the inability of systemic chemotherapy to adequately penetrate the peritoneal surface. Intraperitoneal (IP) chemotherapy has emerged as a potential treatment modality for patients with extensive PM, allowing for higher local drug concentrations while minimizing systemic toxicity. However, current response evaluation methods, such as CT scans, have low sensitivity for detecting PM, and second-look laparoscopy, although more accurate, is invasive and unsuitable for repeated assessments. The ⁶⁸Ga-FAPI PET\u002FCT scan offers a promising non-invasive alternative for assessing peritoneal response to IP chemotherapy. This imaging technique targets the fibroblast activation protein, which is overexpressed in cancer-associated fibroblasts within the tumor microenvironment. Early studies have shown that ⁶⁸Ga-FAPI PET\u002FCT is a highly sensitive too in detecting peritoneal metastases. Given these advantages, the investigators hypothesize that ⁶⁸Ga-FAPI PET\u002FCT could improve the evaluation of treatment response in patients undergoing IP chemotherapy for PM, offering a non-invasive and accurate alternative to current methods. The primary objective of this study is to investigate the accuracy of ⁶⁸Ga-FAPI PET\u002FCT for evaluating peritoneal response in patients with peritoneal metastases undergoing repeated IP chemotherapy.",[29,114],"FAPI",[33,116,114,117],"Intraperitoneal","PET\u002FCT","2025-05-06",{"date":120,"type":43},"2025-05-09",{"date":98,"type":21},{"date":123,"type":21},"2027-03",{"name":125,"class":50},"Erasmus Medical Center",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100586385","phase-2-efficacy-of-tirellizumab-combined-with-oral-intravenous-and-abdominal-chemotherapy-in-peritoneal-metastatic-gastricgastroesophageal-junction-adenocarcinoma-100586385","NCT06914687","Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric\u002FGastroesophageal Junction Adenocarcinoma","Tirellizumab Combined With SOX and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Peritoneal Metastatic Gastric\u002FGastroesophageal Junction Adenocarcinoma: A Single-arm, Phase II Clinical Trial (Solids-03)","Inclusion Criteria:\n\nSigned informed consent Patients age 18-75 years Histologically CT\u002FMRI confirmed cT3-4NanyM1 gastric or GEJ adenocarcinoma; Peritoneal metastasis was confirmed by laparoscopy (with or without Krukenberg tumor ) The degree of peritoneal metastasis ≤P1b or PCI≤13 points ECOG 0-1, no surgery contraindications; Expected survival ≥3 months;\n\nExclusion Criteria:\n\nPrior chemotherapy, radiotherapy, surgery for gastric cancer; Signs of other distant metastases (e.g., liver, lung, bone, supraclavicular lymph, etc.) Significant cardiovascular disease Major surgical procedure within 4 weeks prior to initiation of study treatment Current treatment with anti-viral therapy or HBV Pregnancy or breastfeeding History of malignancy within 5 years prior to screening Present or history of any autoimmune disease or immune deficiency Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent There are active gastric and duodenal ulcers, ulcerative colitis and other gastrointestinal diseases, or active bleeding in unresectable tumors Poorly controlled hypertension or diabetes",{"count":134,"type":21},30,[24],"For peritoneal metastatic gastric\u002Fgastroesophageal junction adenocarcinoma (cT3-4NanyM1), PD-1 antibody combined with chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) can downstage tumor stage, increase the conversion resection rate, and may improve the long-term survival. Tislelizumab, an anti-PD-1 antibody, has recently been proved in the first- and second-line standard treatment for advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.In the subgroup analysis of RATIONALE-305 trial, tislelizumab also showed good efficacy in gastric\u002Fgastroesophageal junction adenocarcinoma patients with peritoneal metastasis. Combination of tirellizumab,SOX and HIPEC for peritoneal metastatic gastric\u002Fgastroesophageal junction adenocarcinoma could be a novel therapeutic strategy to increase response rate and therapeutic efficacy. This study is a monocenter, single-arm phase 2 clinical trial to evaluate tolerability, safety and efficacy of perioperative tirellizumab in combination with SOX and HIPEC in peritoneal metastatic gastric\u002Fgastroesophageal junction adenocarcinoma.",[138,139,29],"Gastric Adenocarcinoma","Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma",[141,29,142],"gastric cancer","Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","2025-03-31",{"date":145,"type":43},"2025-04-06",{"date":147,"type":21},"2025-03-30",{"date":149,"type":21},"2028-04-01",{"name":151,"class":50},"Fudan University",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":160,"studyType":161,"phases":4,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":78},"100562004","the-role-of-18f-fdgamp68ga-fapi-petct-in-the-assessment-of-conversion-therapy-efficacy-in-gastric-cancer-with-peritoneal-metastasis-100562004","NCT06597526","The Role of 18F-FDG&68Ga-FAPI PET\u002FCT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.","The Role of 18F-FDG & 68Ga-FAPI PET\u002FCT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastatic","Inclusion Criteria:\n\n1. Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions\n2. Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction\n3. Patients voluntarily enrolled in this study by signing an informed consent form\n4. Age ≥ 18 years\n5. Eastern Cooperative Oncology Group (ECOG) score ≤ 2,\n6. Expected life expectancy ≥ 3 months\n7. Adequate organ and bone marrow function\n8. Willingness to adhere to the study protocol and follow-up programme\n\nExclusion Criteria:\n\n1. Signs of distant metastases other than peritoneal metastases at enrolment\n2. Pregnant or breastfeeding women.\n3. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix\n4. Severe mental disease, uncontrolled epilepsy, or central nervous system disease",{"count":134,"type":21},"3 Years","OBSERVATIONAL","This study aims to investigate the value of 18F-FDG\\&68Ga-FAPI PET\u002FCT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.",[29,164],"Gastric Cancer",[166,167,141,168,169],"18F-FDG PET\u002FCT","68Ga-FAPI PET\u002FCT","peritoneal metastases","conversion therapy","2024-09-13",{"date":172,"type":43},"2024-09-19",{"date":174,"type":43},"2024-06-15",{"date":176,"type":21},"2029-05-31",{"name":178,"class":50},"Ruijin Hospital"]